PT  - JOURNAL ARTICLE
AU  - Mirthe de Boer
AU  - Paul J van Diest
TI  - Blunt duct adenosis: a separate entity from columnar cell lesions?
AID  - 10.1136/jclinpath-2020-207359
DP  - 2022 Jan 01
TA  - Journal of Clinical Pathology
PG  - 5--9
VI  - 75
IP  - 1
4099  - http://jcp.bmj.com/content/75/1/5.short
4100  - http://jcp.bmj.com/content/75/1/5.full
SO  - J Clin Pathol2022 Jan 01; 75
AB  - Blunt duct adenosis (BDA) is a breast lesion first described by Foote and Stewart in 1945 as a proliferative benign lesion of the terminal duct lobular unit. Throughout recent decades, further literature descriptions of BDA have been confusing. Some consider BDA to be a separate entity, some a growth pattern of columnar cell changes. The WHO 2012 considered BDA and columnar cell changes to be synonyms, while columnar cell lesions, especially those with atypia, are part of a spectrum of early precursors of the low nuclear grade breast neoplasia family. In the updated WHO 2019 version, BDA is mentioned as ‘not recommended’ terminology for columnar cell lesions without further discussing it, leaving the question open if BDA should be considered a separate entity.Good diagnostic criteria for BDA have however largely been lacking, and its biological background has not yet been unravelled. In this paper, we point out that BDA is mainly associated with benign breast lesions and not with other recognised precursor lesions. Further, 16q loss, which is the hallmark molecular event in the low nuclear grade breast neoplasia family, is lacking in BDA. We therefore hypothesise that BDA may not be a true precursor lesion but a benign polyclonal lesion, and propose morphological diagnostic criteria to better differentiate it from columnar cell lesions.